Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioartificial Liver
HepaLife(TM) Releases Positive New Research Results for First-of-Its-Kind Bioartificial Liver
October 8th, 2007
HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625), developer of the first-of-its-kind artificial liver device, announced significant early results of new in-vitro studies involving the Company's patented PICM-19 liver stem cells, which were placed inside its proprietary artificial liver device and were able to favorably produce urea and successfully remove ammonia, a highly toxic by-product which causes brain damage, coma, and even death. "Today's results demonstrate that, while inside our bioartificial liver device, HepaLife's PICM-19 cells are able to produce substantial amounts of urea and remove toxic ammonia, while remaining healthy, and replicating...
Source: Biotech Business Week (2007-10-08)
|
